Does albumin preinfusion potentiate diuretic action of furosemide in patients with nephrotic syndrome?

Journal of Korean Medical Science

Volumn 16, Issue 4, 2001, Pages 448-454

  Na, Ki Young ^a   Han, Jin Suk ^a   Kim, Yon Su ^a   Ahn, Curie ^a   Kim, Suhnggwon ^a   Lee, Jung Sang ^a   Bae, Kyun Sup ^b   Jang, In Jin ^b   Shin, Sang Goo ^b   Huh, Wooseong ^c   Jeon, Un Sil ^c  

^a Seoul National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c Gyeongsang National University   (South Korea)

Author keywords

Albumin Preinfusion; Diuresis; Furosemide; Natriuresis; Nephrotic Syndrome

Indexed keywords

ALBUMINOID; DIURETIC AGENT; FUROSEMIDE; SERUM ALBUMIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG POTENTIATION; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; NEPHROTIC SYNDROME; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; AGED; ALBUMINS; CROSS-OVER STUDIES; DIURETICS; DRUG SYNERGISM; FEMALE; FUROSEMIDE; HUMANS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; SERUM ALBUMIN;

EID: 0035430654     PISSN: 10118934     EISSN: None     Source Type: Journal    
DOI: 10.3346/jkms.2001.16.4.448     Document Type: Article

References (26)

1. Brater DC. Resistance to diuresis: emphasis on a pharmacological perspective. Drugs 1981; 22: 477-94.
2. Inoue M, Okajima K, Itoh K, Ando Y, Watanabe N, Yasaka T, Nagase S, Morino Y. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987; 32: 198-203.
3. Sjöström PA, Odlind BG, Beermann BA, Karlberg BE. Pharmacokinetics and effects of frusemide in patients with the nephrotic syndrome. Eur J Clin Pharmacol 1989; 37: 173-80.
4. Kirchner KA, Voelker JR, Brater DC. Intratubular albumin blunts the response to furosemide- a mechanism for diuretic resistance in the nephrotic syndrome. J Pharmacol Exp Ther 1990; 252: 1097-101.
5. Burg MB. Tubule chloride transport and the mode of action of some diuretics. Kidney Int 1976; 9: 189-97.
6. Seely JF, Dirks JH. Diuretic site of action. Kidney Int 1977; 11: 1-8.
7. Green TP, Mirkin BL. Furosemide disposition in normal and proteinuric rats: urinary drug-protein binding as a determinant of drug excretion. J Pharmacol Exp Ther 1981; 218: 122-7.
8. Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med 1991; 114: 886-94.
9. Akcicek F, Yalniz T, Basci A, Ok E, Mees EJ. Diuretic effect of frusemide in patients with nephrotic syndrome: is it potentiated by intravenous albumin? Br Med J 1995; 310: 162-3.
10. Fliser D, Zurbrüggen I, Mutschler E, Bischoff I, Nussberger J, Franek E, Ritz E. Coadministration of albumin and furosemide in patients with the nephrotic syndrome. Kidney Int 1999; 55: 629-34.
11. Eadington DW, Plant WD, Winney RJ. Albumin in the nephrotic syndrome. Br Med J 1995; 310: 1333.
12. Kim D-H, Earm J-H, Han JS, Kim HY, Oh TG, Huh W, Lee JS, Jang IJ, Shin SG. Does albumin infusion enhance the diuretic action of furosemide in nephrotic syndrome? Korean J Nephrol 1998; 17: 567-73.
13. Farthing D, Karnes T, Gehr TWB, March C, Fakhry I, Sica DA. External-standard high-performance liquid chromatographic method for quantitative determination of furosemide in plasma by using solid-phase extraction and oil-line elation. J Pharm Sci 1992; 81: 569-71.
14. Chennavasin P, Seiwell R, Brater DC, Liang WMM. Pharmacodynamic analysis of the furosemide-probenecid interaction in man. Kidney Int 1979; 16: 187-95.
15. Davison AM, Lambie AT, Verth AH, Cash JD. Salt-poor human albumin in management of nephrotic syndrome. Br Med J 1974; 16: 481-4.
16. Mattana J, Patel, Ilunga C, Singhal PC. Furosemide-albumin complexes in refractory nephrotic syndrome and chronic renal failure. Nephron 1996; 73: 122-3.
17. Aurell M. Renal response in men to plasma volume expansion and angiotensin. Scand J Clin Lab Invest Suppl 1969; 112: 1-59.
18. James J, Gordillo G, Metcoff J. Effects of infusion of hyperoncotic dextran in children with the nephrotic syndrome. J Clin Invest 1954; 33: 1346-57.
19. Orloff J, Welt LG, Stowe L. The effect of concentrated salt-poor albumin on the metabolism and excretion of water and electrolyte in nephrosis and toxemia of pregnancy. J Clin Invest 1950; 29: 770-80.
20. Goldsmith SR, Cowley AW Jr, Francis GS, Cohn JN. Effect of increased intracardiac and arterial pressure on plasma vasopressin in humans. Am J Physiol 1984; 246: H647-51.
21. Atherton JC, Green R, Thomas S. Influence of lysine-vasopressin dosage on the time course of changes in renal tissue and urinary compositon in the conscious rat. J Physiol 1971; 213: 291-309.
22. Dollery C (eds): Therapeutic drugs. London, England, Churchill Livingston, 1993; pp. F. 125-30.
23. Rane A, Villeneuve JP, Stone WJ, Nies AS, Wilkinson GR, Branch RA. Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin. Pharmacol Ther 1978; 24: 199-207.
24. Kirchner KA, Voelker JR, Brater DC. Binding inhibitors restore furosemide potency in tubule fluid containing albumin. Kidney Int 1991; 40: 418-24.
25. Agarwal R, Gorski JC, Sundblad K, Brater DC. Urinary protein binding does not affect response to furosemide in patients with nephrotic syndrome. J Am Soc Nephrol 2000; 11: 1100-5.
26. Okusa MD, Ellison DH. Physiology and pathophysiology of diuretic action. In: Seldin DW, Giebisch G, editors, The Kidney. Philadelphia: Lippincott Williams & Wilkins, 2000; 2878-922.